


EFFECTIVENESS, SAFETY AND PATIENT-REPORTED SATISFACTION OF AUTOLOGOUS SERUM EYE DROPS IN REFRACTORY OCULAR DISEASES: A REAL-WORLD STUDY

BACKGROUND AND IMPORTANCE

Autologous serum eye drops (ASED) are a therapeutic option for severe ocular surface diseases, especially in patients unresponsive to conventional treatments. Their composition, similar to natural tears, promotes healing and symptom's relief. However, evidence on safety and patient satisfaction in real-world practice is scarce

MATERIAL AND METHODS

Retrospective and observational study




- Adults treated with ASED for:
 - Severe dry eye, Sjögren's syndrome, corneal injury, or other refractory ocular diseases.
- Data collected: demographics, diagnosis, VA, ocular symptoms and adverse events (AE).




Effectiveness

Change in VA and symptom (baseline and after 6 months)



Safety

Adverse events



Satisfaction


Treatment Satisfaction Questionnaire for Medication *

* *Treatment Satisfaction Questionnaire for Medication (TSQM v1.4, Spanish version), via telephone, scoring four domains (effectiveness, side effects, convenience, global satisfaction; scale 0-100; positive ≥ 75).*

AIM AND OBJECTIVES

To evaluate the impact of ASED on visual acuity (VA), ocular symptoms, safety, and patient-reported satisfaction in refractory ocular diseases in real-world practice.

RESULTS




Thirty-nine patients were included.

89.7% vs 10.3%

Mean age 66 ± 11.5 years

Diagnoses:


Dry eye (n=22), Sjögren's syndrome (n=7), corneal injury (n=7), others (n=2).

35 patients had completed VA data.
Overall, 40% showed general VA improvement and 40% remained stable. 

Symptom relief was reported by 71.8% of patients, including improvement in dryness (n=10), foreign body sensation (n=6), itching (n=4), pain (n=4), irritation (n=3) and corneal ulcers (n=1).

No **AE** were reported.

TSQM scores (n=34) were: effectiveness 76.8 ± 24.3 (67.6% ≥ 75), side effects 100 ± 0.0 (100% ≥ 75), convenience 77.8 ± 16.4 (58.8% ≥ 75), global satisfaction 84.9 ± 23.8 (85.3% ≥ 75).



CONCLUSION AND RELEVANCE

In real-world practice, ASED achieved high patient-reported satisfaction and significant symptom relief in refractory ocular diseases, with an excellent safety profile, even without measurable VA changes. These findings support ASED as a valuable therapeutic option for patients with limited alternatives and highlight the importance of incorporating patient-reported outcomes in routine ophthalmic care.

